A significant portion of the global population is overweight with rising prevalence and limited effective, safe, and scalable treatment options. LMN-801 is designed as a potential first-in-class, orally delivered biologic that targets metabolic signaling pathways to promote fat loss while preserving lean muscle mass—addressing key drawbacks of existing injectable therapies that often cause muscle wasting. If successful, it could fulfill the unmet need for a highly accessible, globally scalable treatment for overweight individuals.

Traditionally considered a community-acquired infection, C. difficile is more commonly community-acquired today. Long-term consequences include chronic diarrhea, severe intestinal inflammation, surgical resection, and death. Insidiously, the very thing that is used to treat this infection—broad spectrum antibiotics—is also the thing that causes the disease. C. difficile appears near the top of the CDC’s antimicrobial threats list year after year. For these reasons, the orally delivered LMN-201 is an important potential addition.

Inflammatory bowel disease (IBD) is a systemic autoimmune disease, but it has an obvious nexus with the gastrointestinal tract. The two main sub-varieties—Crohn’s disease and ulcerative colitis—have many available treatments on the market today, but it remains a major unmet medical need: current treatments are costly, require inconvenient injection delivery, and come with severe side effects. There are no approved therapies at all for mild-to-moderate Crohn’s. A safe, affordable, orally delivered drug to root out IBD at its source is a straightforward application of Lumen's technology, and would constitute a major advance for the field.

Kidney stones affect millions worldwide, causing significant pain, high recurrence rates, and costly hospital interventions. Current preventive options are limited. Lumen’s novel oral biologic cocktail aims to reduce stone recurrence by targeting metabolic and crystallization pathways in the kidney and urinary tract. If shown safe and effective in an adaptive Phase 2/3 trial, it could represent the first non-invasive, biologic-based preventive therapy for recurrent nephrolithiasis.

Acute gastroenteritis, caused by viral or bacterial pathogens, is a major global burden—especially in children and low-resource settings—leading to dehydration, hospitalizations, and even death. Lumen’s antibody cocktail is designed to neutralize the most common pathogens in the GI tract. Early field and ileostomy pharmacokinetic studies have validated delivery and local action; a proof-of-concept study in 2025 will assess effectiveness in real-world scenarios.

While primarily respiratory illnesses, both influenza and COVID19 can also affect the gastrointestinal tract and are still in need of tolerable, accessible interventions. Lumen’s intranasal biologic aims to deliver neutralizing antibodies directly to the upper respiratory tract to block infection, reduce disease severity, and potentially curb transmission. Pharmacokinetic and tolerability studies planned in 2025 will inform dosing and delivery strategy.

Malaria remains one of the world’s deadliest infectious diseases, with hundreds of millions of cases annually and rising resistance to frontline treatments and insecticides. Despite progress in vaccine development, coverage and durability remain limited, and affordable interventions are still urgently needed. If successful, this could provide a low-cost, stable, and easily distributed adjunct therapy for endemic regions—helping fill a critical gap in malaria control strategies.